摘要
目的比较布地奈德福莫特罗单独治疗与孟鲁司特钠联合布地奈德福莫特罗治疗中重度哮喘的疗效。方法选取中重度哮喘患者66人随机分为两组,布地奈德福莫特罗治疗组(单药组,例数=33)和孟鲁司特钠联合布地奈德福莫特罗治疗组(联合组,例数=33),分别记录2组治疗前、治疗3个月后日间、夜间症状评分,治疗前后一秒钟用力呼气量/用力肺活量(FEV1/FVC%)、嗜酸性粒细胞(EOS)计数。结果联合治疗和单药治疗后哮喘症状评分、EOS计数均较明显低于治疗前,联合组症状改善优于单药组(P<0.05)。2组治疗后FEV1/FVC%均明显上升(P<0.05),联合组较单药组上升更明显(P<0.05)。结论孟鲁司特钠与布地奈德福莫特罗联合治疗中重度哮喘,在消除气道炎症反应中起协同作用。
Objective To evaluate the clinical efficacy of the combination therapy of montelukast and budesonide/foradil powder in the treatment of patients with mild to severe bronchial asthma.Methods Totally 66 patients were randomly divided into budesonide/foradil powder for inhalation group（n=33） and montelukast and budesonide/foradil powder for inhalation group（n=33）.Efficacy was assessed by recording nighttime and daytime symptom scores,before and after treatment of FEV1/FVC%,peripheral blood eosinophil count（EOS） before and after 3 month treatment of two groups.Results Nighttime and daytime symptom scores and peripheral blood eosinophil count（EOS） were reduced in two groups.but was more significant in montelukast and budesonide/foradil powder for inhalation group（P0.05）.Before and after treatment of FEV1/FVC% was also improved in both groups.The improvement of FEV1/FVC% in the montelukast and budesonide/foradil powder for inhalation group was faster than that of budesonide/foradil powder for inhalation group after treatment for 3 months（P0.05）.Conclusions Montelukast and budesonide/foradil powder for inhalation have more rapid improvement and better efficacy than budesonide/foradil powder in the treatment of patients with mild to severe bronchial asthma.
出处
《医药论坛杂志》
2011年第8期72-73,76,共3页
Journal of Medical Forum
